What is the interpretation of Epstein-Barr Virus (EBV) serology results showing elevated EBV Viral Capsid Immunoglobulin G (IgG) and EBV Nuclear Antigen IgG, with normal EBV Viral Capsid Immunoglobulin M (IgM) and EBV Early Antigen IgG, and slightly elevated EBV Heterophile IgM?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The EBV test results indicate a past EBV infection that is not currently active, with elevated EBV Viral Capsid IgG and EBV Nuclear Antigen IgG antibodies, and negative EBV Viral Capsid IgM, EBV Early Antigen IgG, and Heterophile IgM, suggesting a previous infection that has been cleared by the body. The elevated EBV Viral Capsid IgG (6.8) and EBV Nuclear Antigen IgG (2.9) antibodies are markers of previous infection, as these antibodies typically remain positive for life after exposure, as noted in the guidelines for diagnosing EBV infection 1. The negative EBV Viral Capsid IgM (0.2), negative EBV Early Antigen IgG (<0.2), and negative Heterophile IgM (0.8) all suggest this is not an acute or recent infection.

This pattern is consistent with someone who had mononucleosis or an EBV infection sometime in the past, likely months to years ago. The proposed guidelines for diagnosing chronic active EBV infection also support this interpretation, as they recommend the use of EBV antibody testing, including IgG and IgM to viral capsid antigen (VCA) and Epstein-Barr nuclear antigen (EBNA), to differentiate EBV infection from other mononucleosis-like illnesses 1. No specific treatment is needed for past EBV infections as the body has already cleared the active virus. These results simply confirm previous exposure to EBV, which is extremely common, with over 90% of adults worldwide having been infected at some point in their lives.

Some key points to consider in the interpretation of these results include:

  • The presence of EBV antibodies, such as VCA-IgG and EBNA-IgG, which are typically positive for life after exposure 1
  • The absence of EBV IgM antibodies, which suggests that the infection is not acute or recent 1
  • The use of EBV antibody testing to differentiate EBV infection from other mononucleosis-like illnesses 1
  • The fact that past EBV infections do not require specific treatment, as the body has already cleared the active virus.

From the Research

Interpretation of EBV Serological Results

The provided serological results show:

  • EBV Viral Capsid IgG: 6.8 High
  • EBV Viral Capsid IgM: 0.2
  • EBV Nuclear Antigen IgG: 2.9 High
  • EBV Early Ag IgG: <0.2
  • EBV Heterophile IgM: 0.8

Serological Patterns and Infection Status

According to 2, the presence of VCA IgG and EBNA-1 IgG without VCA IgM is typical of past infection. In this case, the high levels of VCA IgG and EBNA-1 IgG, along with low levels of VCA IgM, suggest a past EBV infection.

Diagnostic Challenges and Solutions

As noted in 3, the interpretation of EBV serologies can be challenging due to the various possible serological patterns. However, the use of multiple markers, such as VCA IgG, VCA IgM, and EBNA-1 IgG, can help to define the infection status. In this case, the results are consistent with a past infection.

Assay Performance and Concordance

Studies have evaluated the performance of various EBV antibody assays, including the Architect EBV antibody panel 4, 5, 6. These studies have shown high concordance and good performance of the assays in detecting EBV antibodies and categorizing infection status.

Key Findings

  • The presence of high VCA IgG and EBNA-1 IgG levels, along with low VCA IgM levels, is consistent with a past EBV infection 2.
  • The use of multiple markers can help to define the infection status and solve diagnostic challenges 3.
  • The Architect EBV antibody panel has been shown to have high performance and concordance with other assays 4, 5, 6.

Related Questions

What is the difference between Mononucleosis spot test and Epstein-Barr Virus (EBV) infection?
What is the interpretation of Epstein-Barr Virus (EBV) antibody test results, including EBV Viral Capsid Antigen (VCA) Immunoglobulin M (IgM) and Immunoglobulin G (IgG), and EBV Nuclear Antigen Antibody (EBNA) IgG?
What are the management recommendations for a patient with a past EBV infection?
What is the significance of Epstein-Barr Virus (EBV) Early Antigen D (EA-D) Immunoglobulin G (IgG)?
What is the best serological marker for past Epstein-Barr virus (EBV) infection?
What is the cause of a rash in the axillary and inguinal areas in a 72-year-old male (M)?
What is the average improvement in hemoglobin levels for sickle cell patients compliant with hydroxyurea (Hydroxycarbamide) therapy?
What is the average improvement in hemoglobin (Hb) levels for sickle cell disease patients compliant with hydroxyurea (Hydroxycarbamide) therapy?
Is a positive Monospot (Mononucleosis Spot Test) consistent with a false positive result given the patient's Epstein-Barr Virus (EBV) serology results, including high EBV Viral Capsid Immunoglobulin G (IgG) and EBV Nuclear Antigen IgG, but negative EBV Viral Capsid Immunoglobulin M (IgM) and low EBV Heterophile IgM?
What is the diagnosis for a 42-year-old female patient with polyarthralgia (pain in multiple joints), particularly in the knees and feet, exacerbated by walking, with a history of slightly elevated blood glucose (hyperglycemia) and relief with rubbing and myofascial release, resulting in numbness?
Will gabapentin (Gabapentin) help with sleep disturbances associated with cannabis (marijuana) withdrawal?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.